Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Diabetes Care|January 28, 2021
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER TrialFrederik Persson, Stephen C Bain, Ofri Mosenzon, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|October 5, 2020
Extent and prevalence of post-exercise and nocturnal hypoglycemia following peri-exercise bolus insulin adjustments in individuals with type 1 diabetesOlivia McCarthy, Rachel Deere, Rachel Churm, et al.
BMJ Open Diabetes Research & Care|October 6, 2020
Metabolomic, hormonal and physiological responses to hypoglycemia versus euglycemia during exercise in adults with type 1 diabetesOlivia McCarthy, Jason Pitt, Rachel Churm, et al.
Journal of the American College of Cardiology|March 14, 2020
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart FailureSteven P Marso, Florian M M Baeres, Stephen C Bain, et al.
Diabetes, Obesity & Metabolism|October 15, 2019
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trialsVanita R Aroda, Matthew S Capehorn, Louis Chaykin, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 10, 2021
Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational StudyDavid M Williams, Aliya M Ruslan, Rahim Khan, et al.
Diabetes, Obesity & Metabolism|July 4, 2020
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trialOfri Mosenzon, Stephen C Bain, Hiddo J L Heerspink, et al.
Lancet (London, England)|November 23, 2025
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trialDeborah B Horn, Donna H Ryan, Sanja Giljanovic Kis, et al.
Drugs|June 23, 2021
Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 InhibitorsMarc Evans, Angharad R Morgan, Zaheer Yousef, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trialsSubodh Verma, Darren K McGuire, Stephen C Bain, et al.
Pageof 13